BIOVENTUS INC - A (BVS) Stock Fundamental Analysis
USA - NASDAQ:BVS - US09075A1088 - Common Stock
7.45 USD
-0.03 (-0.4%)
7.45 USD
0 (0%)
Overall BVS gets a fundamental rating of 4 out of 10. We evaluated BVS against 189 industry peers in the Health Care Equipment & Supplies industry. While BVS is still in line with the averages on profitability rating, there are concerns on its financial health. BVS is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
BVS had positive earnings in the past year.
In the past year BVS had a positive cash flow from operations.
In multiple years BVS reported negative net income over the last 5 years.
Of the past 5 years BVS 4 years had a positive operating cash flow.
1.2 Ratios
BVS has a Return On Assets of -0.02%. This is in the better half of the industry: BVS outperforms 71.96% of its industry peers.
BVS has a Return On Equity of -0.10%. This is in the better half of the industry: BVS outperforms 72.49% of its industry peers.
BVS has a better Return On Invested Capital (6.08%) than 80.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.02% | ||
| ROE | -0.1% | ||
| ROIC | 6.08% |
ROA(3y)-11.81%
ROA(5y)-6.59%
ROE(3y)-54.27%
ROE(5y)-31.1%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Operating Margin value of 7.11%, BVS is doing good in the industry, outperforming 74.07% of the companies in the same industry.
BVS's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 67.60%, BVS is in the better half of the industry, outperforming 74.07% of the companies in the same industry.
In the last couple of years the Gross Margin of BVS has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.11% | ||
| PM (TTM) | N/A | ||
| GM | 67.6% |
OM growth 3Y-2.88%
OM growth 5Y-14.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.21%
GM growth 5Y-1.56%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BVS is destroying value.
The number of shares outstanding for BVS has been increased compared to 1 year ago.
BVS has more shares outstanding than it did 5 years ago.
BVS has a better debt/assets ratio than last year.
2.2 Solvency
BVS has an Altman-Z score of 1.12. This is a bad value and indicates that BVS is not financially healthy and even has some risk of bankruptcy.
BVS has a Altman-Z score of 1.12. This is comparable to the rest of the industry: BVS outperforms 52.38% of its industry peers.
The Debt to FCF ratio of BVS is 10.30, which is on the high side as it means it would take BVS, 10.30 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of BVS (10.30) is better than 72.49% of its industry peers.
A Debt/Equity ratio of 1.90 is on the high side and indicates that BVS has dependencies on debt financing.
BVS has a worse Debt to Equity ratio (1.90) than 82.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.9 | ||
| Debt/FCF | 10.3 | ||
| Altman-Z | 1.12 |
ROIC/WACC0.72
WACC8.5%
2.3 Liquidity
BVS has a Current Ratio of 1.48. This is a normal value and indicates that BVS is financially healthy and should not expect problems in meeting its short term obligations.
BVS has a Current ratio of 1.48. This is in the lower half of the industry: BVS underperforms 75.66% of its industry peers.
A Quick Ratio of 0.96 indicates that BVS may have some problems paying its short term obligations.
BVS has a Quick ratio of 0.96. This is in the lower half of the industry: BVS underperforms 78.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.48 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
BVS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.28%, which is quite impressive.
The earnings per share for BVS have been decreasing by -16.93% on average. This is quite bad
BVS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.89%.
The Revenue has been growing by 11.01% on average over the past years. This is quite good.
EPS 1Y (TTM)51.28%
EPS 3Y-16.93%
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)11.89%
Revenue growth 3Y9.98%
Revenue growth 5Y11.01%
Sales Q2Q%-0.23%
3.2 Future
The Earnings Per Share is expected to grow by 28.18% on average over the next years. This is a very strong growth
Based on estimates for the next years, BVS will show a small growth in Revenue. The Revenue will grow by 4.48% on average per year.
EPS Next Y37.53%
EPS Next 2Y33.95%
EPS Next 3Y28.18%
EPS Next 5YN/A
Revenue Next Year0.32%
Revenue Next 2Y3.71%
Revenue Next 3Y4.48%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 12.63 indicates a correct valuation of BVS.
88.36% of the companies in the same industry are more expensive than BVS, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of BVS to the average of the S&P500 Index (26.06), we can say BVS is valued rather cheaply.
The Price/Forward Earnings ratio is 8.83, which indicates a very decent valuation of BVS.
Based on the Price/Forward Earnings ratio, BVS is valued cheaply inside the industry as 94.71% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 32.73. BVS is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.63 | ||
| Fwd PE | 8.83 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BVS is valued cheaply inside the industry as 89.42% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, BVS is valued cheaply inside the industry as 87.83% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.06 | ||
| EV/EBITDA | 10.53 |
4.3 Compensation for Growth
BVS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BVS's earnings are expected to grow with 28.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y33.95%
EPS Next 3Y28.18%
5. Dividend
5.1 Amount
BVS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.45
-0.03 (-0.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners73.56%
Inst Owner Change-0.16%
Ins Owners2.54%
Ins Owner Change3.12%
Market Cap615.97M
Revenue(TTM)573.28M
Net Income(TTM)-158.00K
Analysts80
Price Target14.96 (100.81%)
Short Float %3.24%
Short Ratio6.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)119.26%
Min EPS beat(2)-0.99%
Max EPS beat(2)239.51%
EPS beat(4)3
Avg EPS beat(4)103.69%
Min EPS beat(4)-0.99%
Max EPS beat(4)239.51%
EPS beat(8)7
Avg EPS beat(8)172.93%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.02%
Min Revenue beat(2)-0.04%
Max Revenue beat(2)0.07%
Revenue beat(4)3
Avg Revenue beat(4)2.02%
Min Revenue beat(4)-0.04%
Max Revenue beat(4)4.79%
Revenue beat(8)7
Avg Revenue beat(8)4.23%
Revenue beat(12)9
Avg Revenue beat(12)1.98%
Revenue beat(16)11
Avg Revenue beat(16)1.72%
PT rev (1m)0%
PT rev (3m)4.76%
EPS NQ rev (1m)-1.43%
EPS NQ rev (3m)-29.59%
EPS NY rev (1m)-0.52%
EPS NY rev (3m)-9.43%
Revenue NQ rev (1m)0.4%
Revenue NQ rev (3m)-0.6%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.25%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.63 | ||
| Fwd PE | 8.83 | ||
| P/S | 1.09 | ||
| P/FCF | 18.06 | ||
| P/OCF | 16.99 | ||
| P/B | 3.82 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.53 |
EPS(TTM)0.59
EY7.92%
EPS(NY)0.84
Fwd EY11.32%
FCF(TTM)0.41
FCFY5.54%
OCF(TTM)0.44
OCFY5.88%
SpS6.82
BVpS1.95
TBVpS-2.82
PEG (NY)0.34
PEG (5Y)N/A
Graham Number5.09
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.02% | ||
| ROE | -0.1% | ||
| ROCE | 7.7% | ||
| ROIC | 6.08% | ||
| ROICexc | 6.49% | ||
| ROICexgc | 33.79% | ||
| OM | 7.11% | ||
| PM (TTM) | N/A | ||
| GM | 67.6% | ||
| FCFM | 6.04% |
ROA(3y)-11.81%
ROA(5y)-6.59%
ROE(3y)-54.27%
ROE(5y)-31.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y44.62%
ROICexgc growth 5Y-8.7%
ROICexc growth 3Y36.86%
ROICexc growth 5Y-12.41%
OM growth 3Y-2.88%
OM growth 5Y-14.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.21%
GM growth 5Y-1.56%
F-Score7
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.9 | ||
| Debt/FCF | 10.3 | ||
| Debt/EBITDA | 3.46 | ||
| Cap/Depr | 4.42% | ||
| Cap/Sales | 0.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 40.86% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.48 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | 1.12 |
F-Score7
WACC8.5%
ROIC/WACC0.72
Cap/Depr(3y)9.96%
Cap/Depr(5y)13.06%
Cap/Sales(3y)1.19%
Cap/Sales(5y)1.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.28%
EPS 3Y-16.93%
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y37.53%
EPS Next 2Y33.95%
EPS Next 3Y28.18%
EPS Next 5YN/A
Revenue 1Y (TTM)11.89%
Revenue growth 3Y9.98%
Revenue growth 5Y11.01%
Sales Q2Q%-0.23%
Revenue Next Year0.32%
Revenue Next 2Y3.71%
Revenue Next 3Y4.48%
Revenue Next 5YN/A
EBIT growth 1Y188.15%
EBIT growth 3Y6.82%
EBIT growth 5Y-5.11%
EBIT Next Year16.75%
EBIT Next 3Y12.98%
EBIT Next 5YN/A
FCF growth 1Y336.04%
FCF growth 3Y34.24%
FCF growth 5Y-0.3%
OCF growth 1Y103.28%
OCF growth 3Y19.05%
OCF growth 5Y-0.96%
BIOVENTUS INC - A / BVS FAQ
Can you provide the ChartMill fundamental rating for BIOVENTUS INC - A?
ChartMill assigns a fundamental rating of 4 / 10 to BVS.
What is the valuation status of BIOVENTUS INC - A (BVS) stock?
ChartMill assigns a valuation rating of 8 / 10 to BIOVENTUS INC - A (BVS). This can be considered as Undervalued.
Can you provide the profitability details for BIOVENTUS INC - A?
BIOVENTUS INC - A (BVS) has a profitability rating of 4 / 10.
How financially healthy is BIOVENTUS INC - A?
The financial health rating of BIOVENTUS INC - A (BVS) is 2 / 10.
What is the earnings growth outlook for BIOVENTUS INC - A?
The Earnings per Share (EPS) of BIOVENTUS INC - A (BVS) is expected to grow by 37.53% in the next year.